Drugs in Dev. Dermatology
Phase III
France 
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The safety results of the trial were generally consistent with the known safety profile of Dupixent in its approved indications. The occurrences of treatment-emergent adverse events were generally similar between Dupixent and placebo groups (57% Dupixent...
Product Name : Dupixent
Product Type : Antibody
Upfront Cash : Inapplicable
October 22, 2021
Lead Product(s) : Dupilumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipsen Updates on QM-1114 Regulatory Process
Details : QM-1114 (botulinum toxin type A) liquid is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for movement disorders such as cervical dystonia.
Product Name : Dysport
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
